Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05063851 · ClinicalTrials.gov registry record · Phase 2
The Use of Memantine for Prevention of Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by University of Virginia.
- Active
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05063851 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 32 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05063851, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
As the US population ages, the prevalence of dementia is increasing, and Alzheimer's Disease (AD) is the most prevalent one. Solving the Alzheimer's Disease (AD) epidemic is likely to require preventive therapy beginning many years before symptoms are expected to be evident in at-risk individuals. AD is caused by the dysfunction, loss of synapses, and eventual neuronal death, which may occur up to 25 years before clinical symptoms appear. This study, based off of pre-clinical data, seeks to assess whether it is feasible to use memantine hydrochloride for the prevention of Alzheimer's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Memantine Hydrochloride Tablets
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05063851
The ClinicalTrials.gov registry entry for NCT05063851 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05063851 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05063851 about?
NCT05063851 is a clinical study titled "The Use of Memantine for Prevention of Alzheimer's Disease". As the US population ages, the prevalence of dementia is increasing, and Alzheimer's Disease (AD) is the most prevalent one. Solving the Alzheimer's Disease (AD) epidemic is likely to require preventive therapy beginning many years before symptoms are expected to be evident in at-risk individuals. A...
What is the current status of trial NCT05063851?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2021-10-11. Estimated completion is 2026-12.
What conditions does trial NCT05063851 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05063851?
The interventions under investigation include: Placebo (DRUG), Memantine Hydrochloride Tablets (DRUG).
Who is sponsoring clinical trial NCT05063851?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05063851 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.